<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03148496</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-17-0063</org_study_id>
    <nct_id>NCT03148496</nct_id>
  </id_info>
  <brief_title>Tissue Reinforcement of Incisional Closure Among High Risk Patients</brief_title>
  <official_title>Tissue Reinforcement of Incisional Closure Among High Risk Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      Half of all individuals will undergo abdominal surgery in their lifetime. Following abdominal
      surgery, 30% of patients will suffer a major chronic complication with their wound closure in
      the first post-operative year. This may include significant wound infections, open wounds,
      fluid collections, fascial dehiscence, or incisional hernia. These complications not only
      have a substantial impact on the health care system (cost and chronic disease) and the
      hospital (cost and space), but most importantly have a substantial impact on the patient.
      Major chronic wound complications adversely impact patient quality of life and function.
      Potential methods to reduce major wound complications include utilizing specific suturing
      techniques or reinforcing the incision line. Suturing technique of small-bites (0.5x0.5 cm
      bites) as opposed to large bites (1.0x1.0 cm bites) has been shown to be efficacious in
      European populations with a typical body mass index of 20-25 kg/m2. Tissue reinforcement has
      been shown to decrease rates of major wound complications in small randomized controlled
      trials.

      However, the lack of widespread adoption of these practices may be due to issues of
      generalizability including strict inclusion criteria, careful patient selection, and small
      study size. For example, the generalizability of small bites to an overweight population
      (mean BMI in the United States is 28 kg/m2) as opposed to a normal-weight population are
      unclear. The use of synthetic materials in comorbid patients or complex settings may risk
      major wound complications such as prosthetic infection. Biologic materials have been shown to
      be effective in decreasing major wound complications but in different settings. This study is
      being done to assess the effectiveness of different efficacious strategies to decrease the
      rate of major wound complications following abdominal surgery among high-risk individuals The
      researchers hypothesize:

        1. Among high-risk patients undergoing abdominal surgery, the use of &quot;small-bites&quot; closure
           as opposed to &quot;large-bites&quot; closure will increase the proportion of patients who are
           free of major, chronic wound complications at 1-year post-operative.

        2. Among high-risk patients undergoing abdominal surgery, the biologic tissue reinforcement
           of the suture line as opposed to no reinforcement will increase the proportion of
           patients who are free of major, chronic wound complications at 1-year post-operative.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Chronic Wound Infection</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>Proportion of patients with major chronic wound infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dindo-Clavien complications</measure>
    <time_frame>1 month after surgery, 1 year after surgery, and 3 years after surgery</time_frame>
    <description>Defined by the CDC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical site infections</measure>
    <time_frame>1 month after surgery, 1 year after surgery, and 3 years after surgery</time_frame>
    <description>Defined by the CDC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperations</measure>
    <time_frame>1 month after surgery, 1 year after surgery, and 3 years after surgery</time_frame>
    <description>any unplanned invasive procedure involving the fascia, mesh, or peritoneal cavity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative duration</measure>
    <time_frame>time of incision to end surgery time</time_frame>
    <description>length of the entire procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient centered outcomes-Activities Assessment Scale</measure>
    <time_frame>1 month after surgery, 1 year after surgery, and 3 years after surgery</time_frame>
    <description>based upon the modified Activities Assessment Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient centered outcomes--Euroqol-5D</measure>
    <time_frame>1 month after surgery, 1 year after surgery, and 3 years after surgery</time_frame>
    <description>based upon the Euroqol-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost analyses</measure>
    <time_frame>1 month after surgery, 1 year after surgery, and 3 years after surgery</time_frame>
    <description>calculated from the hospital's perspective by assessing charges for all patient visits, admissions, and procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgeon perception</measure>
    <time_frame>1 year after surgery, and 3 years after surgery</time_frame>
    <description>likert type and open ended questions assessing perception, barriers and likelihood of utilizing interventions outside of the trial</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Wound Complication</condition>
  <arm_group>
    <arm_group_label>Biologic Mesh and Small Bytes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biologic mesh placement and small bytes used for suturing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Small Bytes and No Biologic Mesh</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Small bytes used for suturing with no placement of biologic mesh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biologic mesh and Large Bytes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biologic mesh placement and large bytes used for suturing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Large Bytes and no biologic mesh</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Large bytes used for suturing and no placement of biologic mesh.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biologic Mesh</intervention_name>
    <description>Biologic mesh placed during surgery</description>
    <arm_group_label>Biologic Mesh and Small Bytes</arm_group_label>
    <arm_group_label>Biologic mesh and Large Bytes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Small Bytes</intervention_name>
    <description>0.5 cm x 0.5 cm sutures used</description>
    <arm_group_label>Biologic Mesh and Small Bytes</arm_group_label>
    <arm_group_label>Small Bytes and No Biologic Mesh</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Large Bytes</intervention_name>
    <description>1.0 x 1.0 sutures used</description>
    <arm_group_label>Biologic mesh and Large Bytes</arm_group_label>
    <arm_group_label>Large Bytes and no biologic mesh</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All high-risk patients undergoing laparotomy or laparoscopic-assisted abdominal surgery.
        This includes:

          1. all overweight patients (BMI&gt;=25 kg/m2),

          2. current smokers,

          3. those who are immunosuppressed,

          4. those who are malnourished, or

          5. those who are undergoing a contaminated case (CDC wound classification of 2 or 3).

        Exclusion Criteria:

          1. patients unlikely to follow-up in a year (e.g. no phone or lives out of state),

          2. patients unlikely to survive more than 2 years based upon surgeon judgment (e.g.
             metastatic cancer, end-stage cirrhosis),

          3. patients where the clinician would not place prosthetic (e.g. pregnant patient,
             pediatric patient during growth stage),

          4. patient has a planned second surgery within the next year (e.g. ostomy reversal).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mike K Liang, MD</last_name>
    <phone>713-566-5098</phone>
    <email>Mike.K.Liang@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Debbie F Lew, MPH</last_name>
    <phone>713-566-5097</phone>
    <email>Debbie.F.Lew@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UT Health at Lyndon B. Johnson General Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike K Liang, MD</last_name>
      <phone>713-566-5098</phone>
      <email>Mike.K.Liang@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Debbie F Lew, MPH</last_name>
      <phone>713-566-5097</phone>
      <email>Debbie.F.Lew@uth.tmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mike K Liang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Askenasy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefano Millas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Curtis Wray, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.cdc.gov/infectioncontrol/guidelines/ssi/index.html</url>
    <description>Guidelines for surgical site infections</description>
  </link>
  <reference>
    <citation>Goodenough CJ, Ko TC, Kao LS, Nguyen MT, Holihan JL, Alawadi Z, Nguyen DH, Flores JR, Arita NT, Roth JS, Liang MK. Development and validation of a risk stratification score for ventral incisional hernia after abdominal surgery: hernia expectation rates in intra-abdominal surgery (the HERNIA Project). J Am Coll Surg. 2015 Apr;220(4):405-13. doi: 10.1016/j.jamcollsurg.2014.12.027. Epub 2015 Jan 2.</citation>
    <PMID>25690673</PMID>
  </reference>
  <reference>
    <citation>Armañanzas L, Ruiz-Tovar J, Arroyo A, García-Peche P, Armañanzas E, Diez M, Galindo I, Calpena R. Prophylactic mesh vs suture in the closure of the umbilical trocar site after laparoscopic cholecystectomy in high-risk patients for incisional hernia. A randomized clinical trial. J Am Coll Surg. 2014 May;218(5):960-8. doi: 10.1016/j.jamcollsurg.2014.01.049. Epub 2014 Feb 18.</citation>
    <PMID>24680572</PMID>
  </reference>
  <reference>
    <citation>McCarthy M Jr, Jonasson O, Chang CH, Pickard AS, Giobbie-Hurder A, Gibbs J, Edelman P, Fitzgibbons R, Neumayer L. Assessment of patient functional status after surgery. J Am Coll Surg. 2005 Aug;201(2):171-8. Erratum in: J Am Coll Surg. 2005 Nov;201(5):826.</citation>
    <PMID>16038812</PMID>
  </reference>
  <reference>
    <citation>Hawn MT, Itani KM, Giobbie-Hurder A, McCarthy M Jr, Jonasson O, Neumayer LA. Patient-reported outcomes after inguinal herniorrhaphy. Surgery. 2006 Aug;140(2):198-205.</citation>
    <PMID>16904970</PMID>
  </reference>
  <reference>
    <citation>Blackstock R, Hernandez NC. Characterization of the macrophage subset affected and its response to a T suppressor factor (TsFmp) found in cryptococcosis. Infect Immun. 1989 Oct;57(10):2931-7.</citation>
    <PMID>2777368</PMID>
  </reference>
  <reference>
    <citation>Holihan JL, Henchcliffe BE, Mo J, Flores-Gonzalez JR, Ko TC, Kao LS, Liang MK. Is Nonoperative Management Warranted in Ventral Hernia Patients With Comorbidities?: A Case-matched, Prospective, Patient-centered Study. Ann Surg. 2016 Oct;264(4):585-90. doi: 10.1097/SLA.0000000000001865.</citation>
    <PMID>27355269</PMID>
  </reference>
  <reference>
    <citation>Deerenberg EB, Harlaar JJ, Steyerberg EW, Lont HE, van Doorn HC, Heisterkamp J, Wijnhoven BP, Schouten WR, Cense HA, Stockmann HB, Berends FJ, Dijkhuizen FPH, Dwarkasing RS, Jairam AP, van Ramshorst GH, Kleinrensink GJ, Jeekel J, Lange JF. Small bites versus large bites for closure of abdominal midline incisions (STITCH): a double-blind, multicentre, randomised controlled trial. Lancet. 2015 Sep 26;386(10000):1254-1260. doi: 10.1016/S0140-6736(15)60459-7. Epub 2015 Jul 15.</citation>
    <PMID>26188742</PMID>
  </reference>
  <reference>
    <citation>Millbourn D, Cengiz Y, Israelsson LA. Effect of stitch length on wound complications after closure of midline incisions: a randomized controlled trial. Arch Surg. 2009 Nov;144(11):1056-9. doi: 10.1001/archsurg.2009.189.</citation>
    <PMID>19917943</PMID>
  </reference>
  <reference>
    <citation>Millbourn D, Cengiz Y, Israelsson LA. Risk factors for wound complications in midline abdominal incisions related to the size of stitches. Hernia. 2011 Jun;15(3):261-6. doi: 10.1007/s10029-010-0775-8. Epub 2011 Jan 30.</citation>
    <PMID>21279664</PMID>
  </reference>
  <reference>
    <citation>Bhangu A, Fitzgerald JE, Singh P, Battersby N, Marriott P, Pinkney T. Systematic review and meta-analysis of prophylactic mesh placement for prevention of incisional hernia following midline laparotomy. Hernia. 2013 Aug;17(4):445-55. doi: 10.1007/s10029-013-1119-2. Epub 2013 May 28. Review.</citation>
    <PMID>23712289</PMID>
  </reference>
  <reference>
    <citation>Fortelny RH, Hofmann A, May C, Köckerling F; BioMesh Study Group. Prevention of a Parastomal Hernia by Biological Mesh Reinforcement. Front Surg. 2015 Oct 22;2:53. doi: 10.3389/fsurg.2015.00053. eCollection 2015. Review.</citation>
    <PMID>26557646</PMID>
  </reference>
  <reference>
    <citation>Muysoms FE, Detry O, Vierendeels T, Huyghe M, Miserez M, Ruppert M, Tollens T, Defraigne JO, Berrevoet F. Prevention of Incisional Hernias by Prophylactic Mesh-augmented Reinforcement of Midline Laparotomies for Abdominal Aortic Aneurysm Treatment: A Randomized Controlled Trial. Ann Surg. 2016 Apr;263(4):638-45. doi: 10.1097/SLA.0000000000001369.</citation>
    <PMID>26943336</PMID>
  </reference>
  <reference>
    <citation>Sarr MG, Hutcher NE, Snyder S, Hodde J, Carmody B. A prospective, randomized, multicenter trial of Surgisis Gold, a biologic prosthetic, as a sublay reinforcement of the fascial closure after open bariatric surgery. Surgery. 2014 Oct;156(4):902-8. doi: 10.1016/j.surg.2014.06.022.</citation>
    <PMID>25239343</PMID>
  </reference>
  <reference>
    <citation>Bali C, Papakostas J, Georgiou G, Kouvelos G, Avgos S, Arnaoutoglou E, Papadopoulos G, Matsagkas M. A comparative study of sutured versus bovine pericardium mesh abdominal closure after open abdominal aortic aneurysm repair. Hernia. 2015 Apr;19(2):267-71. doi: 10.1007/s10029-014-1262-4. Epub 2014 May 13.</citation>
    <PMID>24820007</PMID>
  </reference>
  <reference>
    <citation>Ferzoco SJ. A systematic review of outcomes following repair of complex ventral incisional hernias with biologic mesh. Int Surg. 2013 Oct-Dec;98(4):399-408. doi: 10.9738/INTSURG-D-12-00002.1. Review.</citation>
    <PMID>24229031</PMID>
  </reference>
  <reference>
    <citation>Stampfer MJ, Buring JE, Willett W, Rosner B, Eberlein K, Hennekens CH. The 2 x 2 factorial design: its application to a randomized trial of aspirin and carotene in U.S. physicians. Stat Med. 1985 Apr-Jun;4(2):111-6.</citation>
    <PMID>4023472</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2017</study_first_submitted>
  <study_first_submitted_qc>May 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Mike K Liang</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>abdominal surgery</keyword>
  <keyword>wound complication</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

